首页 | 本学科首页   官方微博 | 高级检索  
     


Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study
Authors:Vécsei L  Gallacchi G  Sági I  Semjén J  Tajti J  Szok D  Müller M  Vadass P  Kerékgyártó M
Affiliation:Department of Neurology, Albert Szent-Gy?rgyi Medical and Pharmaceutical Centre, University of Szeged and Neurology Research Group of the Hungarian Academy of Sciences and University of Szeged, Szeged, Hungary. giuseppe.mautone@ibsa.ch
Abstract:Hydrosoluble diclofenac epolamine (DHEP) represents an interesting approach to acute migraine attacks, where gastrointestinal motility and drug absorption are often reduced. Its efficacy was investigated in a randomized, crossover, double-blind trial on 155 patients who treated four consecutive mild-to-moderate migraine attacks, either with DHEP (65-mg sachet) or placebo. If pain was not relieved within 1 h, a second dose was given. The total number of treated attacks was 481. A pain-free condition was achieved within 2 h in 45.8% and 25.1% of attacks treated, respectively, with DHEP or placebo (P < 0.0001), with a therapeutic gain of 20.7%. Time to attack resolution, light and noise sensitivity and impact on working ability were significantly reduced by DHEP compared with placebo. Moreover, significantly fewer patients required a second drug dose or a rescue medication when treated with DHEP than with placebo. No adverse reaction was recorded. In conclusion, DHEP was effective and safe for pain relief in patients with an acute mild-to-moderate migraine attack.
Keywords:Diclofenac    epolamine    migraine    randomized clinical trial
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号